Sutro Biopharma, Inc. (STRO)
| Market Cap | 163.03M +136.3% |
| Revenue (ttm) | 45.11M -57.3% |
| Net Income | -155.27M |
| EPS | -11.32 |
| Shares Out | 16.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 333,445 |
| Open | 10.09 |
| Previous Close | 9.59 |
| Day's Range | 9.08 - 10.29 |
| 52-Week Range | 7.15 - 43.85 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 44.62 (+354.38%) |
| Earnings Date | Nov 12, 2026 |
About STRO
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin... [Read more]
Financial Performance
In 2025, Sutro Biopharma's revenue was $102.48 million, an increase of 65.18% compared to the previous year's $62.04 million. Losses were -$191.09 million, -15.99% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price target is $44.62, which is an increase of 354.38% from the latest price.
News
Sutro Biopharma price target lowered to $25 from $60 at Wedbush
Wedbush lowered the firm’s price target on Sutro Biopharma (STRO) to $25 from $60 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 earnings…
Sutro Biopharma price target raised to $57 from $56 at Barclays
Barclays analyst Lukas Shumway raised the firm’s price target on Sutro Biopharma (STRO) to $57 from $56 and keeps an Overweight rating on the shares post the Q3 report. The…
Sutro Biopharma reports Q3 EPS ($1.90), consensus ($1.96)
Reports Q3 revenue $9.1M, consensus $14.12M. “Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic…
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –
Sutro Biopharma Earnings release: Q3 2026
Sutro Biopharma released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Sutro Biopharma Quarterly report: Q3 2026
Sutro Biopharma has published its Q3 2026 quarterly earnings report on November 12, 2026.
Sutro Biopharma Slides: Corporate presentation
Sutro Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on November 12, 2026.
Sutro Biopharma Transcript: Stifel 2026 Healthcare Conference 2026
STRO-004 showed early activity across several tumor types with low hematologic toxicity, and an expanded update is planned for H1 2027. STRO-006 data are expected in H2 2027, while STRO-227 is on track for an IND later in 2026.
Sutro Biopharma Slides: Investor presentation
Sutro Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
3 ‘Strong Buy’ High-Risk Stocks That Could Offer Mouthwatering Returns
Sutro Biopharma ($STRO), Backblaze ($BLZE), and Ultra Clean Holdings ($UCTT) are three high-risk, high-reward stocks analysts see as having massive upside potential. Wall Street rates each a Strong Bu...
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...
Sutro Biopharma doses first patient in STRO-006 trial
Sutro Biopharma (STRO) announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of solid tumors. STRO-006 is the company’s…
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
— STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026...
Sutro Biopharma appoints Donigian as SVP, Business Development
Sutro Biopharma (STRO) announced the appointment of Lucas Donigian as Senior Vice President, SVP, Business Development, effective September 28, 2026. Donigian brings more than 20 years of biotechnolog...
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...
Sutro Biopharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Three clinical programs advanced ahead of schedule, with STRO-004 showing strong early efficacy and safety across multiple tumor types. Dual payload ADCs demonstrate potential to overcome resistance, supported by robust preclinical and emerging clinical data.
Sutro Biopharma reports Q2 EPS ($2.33), consensus ($2.27)
Reports Q2 revenue $9.84M, consensus $11.04M. “During the second quarter, we continued to execute swiftly across our next-generation ADC portfolio, highlighted by encouraging early clinical data from ...
H.C. Wainwright calls Sutro drop ‘an overreaction’ to limited STRO-004 data
H.C. Wainwright believes Sutro Biopharma’s (STRO) shares are trading lower largely on an overreaction to the limited efficacy disclosure for STRO-004. The firm thinks investors were looking for a more...
Sutro Biopharma price target lowered to $34 from $41 at Citizens
Citizens lowered the firm’s price target on Sutro Biopharma (STRO) to $34 from $41 and keeps an Outperform rating on the shares following the Q2 results and initial STRO-004 clinical…
Sutro Biopharma Slides: Corporate presentation
Sutro Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study –...
Sutro Biopharma Earnings release: Q2 2026
Sutro Biopharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Sutro Biopharma Quarterly report: Q2 2026
Sutro Biopharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
Sutro Biopharma initiated with a Buy at Stifel
Stifel analyst Laura Prendergast initiated coverage of Sutro Biopharma (STRO) with a Buy rating and $48 price target The antibody-drug conjugates space is rapidly growing with about $20B in combined…
Sutro Biopharma assumed with a Buy at Truist
Truist assumed coverage of Sutro Biopharma (STRO) with a Buy rating and $50 price target The company’s refreshed ADC platform is increasingly compelling with multiple opportunities to generate proof-o...